Keeping Track: New Drugs For Glaucoma, Sickle Cell Submitted; IDegLira, Brineura Reviews Extended; Keytruda Advances In First-Line NSCLC

The latest drug development news and highlights from our FDA Performance Tracker.

While FDA remains quiet on the approval front, the agency's dance card for 2017 continues to fill. New submissions this week include a new molecular entity eye drug, the first drug intended to head off sickle cell crises in children, and another priority review supplemental indication for Merck & Co. Inc.'s cancer immunotherapy Keytruda (accompanied by another breakthrough therapy designation).

FDA action was delayed by three-month user fee extensions for BioMarin Pharmaceutical Inc.'s breakthrough-designated orphan drug Brinuera and

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America